MyoKardia, Inc (acquired by BMS)
1000 Sierra Point Parkway
Brisbane, CA 94005
United States
Tel: 650-741-0900
Website: http://www.myokardia.com/
Email: info@myokardia.com
About MyoKardia, Inc (acquired by BMS)
MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science. MyoKardia is a clinical-stage bio pharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by 1) understanding the bio mechanical underpinnings of disease; 2) targeting the proteins that modulate a given condition; 3) identifying patient populations with shared disease characteristics; and 4) applying learnings from research and clinical studies to inform and guide pipeline growth and product advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224. Founded in September 2012 MyoKardia is headquartered in Brisbane, CA.
126 articles about MyoKardia, Inc (acquired by BMS)
-
MyoKardia to Present at 2019 BMO Prescriptions for Success Healthcare Conference
6/18/2019
MyoKardia, Inc. announced that Jake Bauer, Chief Business Officer, will participate in a fireside chat at the 2019 BMO Prescriptions for Success Healthcare Conference on Tuesday, June 25th, 2019, at 1:20 p.m. ET in New York, NY.
-
MyoKardia Presents Results from Phase 1a Clinical Trial of MYK-491 at the European Society of Cardiology Heart Failure Congress in Athens, Greece
5/28/2019
MyoKardia, Inc., presented data at the European Society of Cardiology Heart Failure Congress from its Phase 1a single-ascending dose study of MYK-491 in healthy volunteers.
-
MyoKardia Reports First Quarter 2019 Financial Results
5/9/2019
MyoKardia, Inc. reported financial results for the quarter ended March 31, 2019.
-
MyoKardia to Present at Bank of America Merrill Lynch 2019 Health Care Conference
5/8/2019
MyoKardia, Inc. announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15th, 2019, at 8:40 a.m. PT (11:40 a.m. ET) in Las Vegas, NV.
-
MyoKardia Announces Inaugural MyoSeeds™ Research Grants Program Awardees
5/7/2019
Three Researchers Awarded $250,000 Each to Advance Independent Research in Cardiac Diseases
-
MyoKardia to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
5/2/2019
MyoKardia, Inc. announced that it will report first quarter 2019 financial and operating results on Thursday, May 9, 2019.
-
Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine
4/30/2019
Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine
-
MyoKardia Announces Pricing of Public Offering of Common Stock.
3/26/2019
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced the pricing of an underwritten public offering of 4,925,000 shares of its common stock at a public offering price of $51.00per share, before underwriting discounts.
-
MyoKardia Announces Proposed Public Offering of Common Stock.
3/25/2019
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering to sell $200,000,000 in shares of its common stock.
-
MyoKardia to Present at Cowen & Co. 39th Annual Health Care Conference
3/6/2019
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the Cowen & Co. 39th Annual Health Care Conference on Wednesday, March 13th, 2019, at 10:40 a.m. ET in Boston, MA.
-
MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM
3/4/2019
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced positive 12- and 24-week safety, efficacy and biomarker data for its investigational drug, mavacamten.
-
MyoKardia Reports Fourth Quarter and Full Year 2018 Financial Results
2/28/2019
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018.
-
Thirteen of those were development programs, the remaining 25 research-stage. In September, the company indicated it was on a cost-cutting program, planning to save 1.5 billion euros this year. Of the programs it is dumping, the most prominent is a mid-phase drug for respiratory syncytial virus (...
-
MyoKardia Appoints William Fairey as Chief Commercial Officer
1/23/2019
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of William C. Fairey as Chief Commercial Officer and Executive Vice President.
-
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 30 Life Science Startups to Watch in the U.S. from 2015.
-
MyoKardia to Present at 37th Annual J.P. Morgan Healthcare Conference
1/3/2019
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7th, 2019, at 8:30 a.m. PT (11:30 a.m. ET) in San Francisco.
-
MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi
1/2/2019
Management to Host Conference Call at 8:30 a.m. ET/5:30 a.m. PT
-
Acer Therapeutics, headquartered in Newton, Mass., in-licensed osanetant, a clinical-stage, selective, non-peptide tachykinin NK3 receptor antagonist from Paris-based Sanofi.
-
MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy
6/26/2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that the first patient has been dosed in the company’s Phase 3 EXPLORER-HCM clinical trial.
-
MyoKardia Announces Pricing of Public Offering of Common Stock May 22
5/22/2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a public offering price of $49.00 per share, before underwriting discounts. In addition, the underwriters have a 30-day option to purchase an additional 562,500 shares of common stock on the same terms and conditions.